Preclinical research raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-03-06. Anything still debated is marked as such rather than presented as settled.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
| Property | Value | Notes |
|---|---|---|
| Primary proposed target | HGF/c-Met signaling | Direct binding not confirmed |
| Research models | Rodent and cell studies | Preclinical only |
| Human clinical data | None published | Safety and efficacy unknown |
| Regulatory status | Unapproved research chemical | Status varies by country |
| Typical research purity | 95% or higher by HPLC | Depends on supplier and batch |
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
=== Railway === Wilmslow railway station lies on the Crewe to Manchester spur of the West Coast Main Line, via Stockport. The station is also a junction for the Styal Line, which takes a different route to Manchester Piccadilly, via Styal, Manchester Airport and Heald Green, but avoiding Stockport. The station is served by three train operating companies:
== External links == Official website Duncan Sheik at the Internet Broadway Database Duncan Sheik at IMDb Duncan Sheik at Rounder Records Duncan Sheik discography at Discogs Duncan Sheik at International Songwriters Association
==== Animals ==== HIC in animal tissues is hard to estimate due to complexities in the diet intake and the isotopic composition of surrounding water sources. When fish species were investigated, average HIC of proteins was in a large range of −128‰ ~ +203‰. In the bulk tissue of organisms, all lipids were found to be D-depleted, and the values of δD for lipids tend to be lower than that for proteins. The average δD for Chironomid and fish protein was estimated to be in the range of −128‰ to +203‰. Most hydrogen in heterotrophic tissues comes from water not from diet sources, but the proportion coming from water varies. In general, hydrogen from water is transferred to NADPH and then taken up to the tissues. An apparent trophic effect (compounding effect) can be observed for δD in heterotrophs, so significant D-enrichments result from the intake of surrounding water the in aquatic food webs. The δD of proteins in animal tissues are in cases affected more by diet sources than by surrounding water. Though different δDs for the same class of compounds may arise in different organisms growing in water with the same δD, those compounds generally have the same δD within each organism itself. [See Section 7.5. Ecology for more details]
Sources: en.wikipedia.org
In a detailed case study on unusual morphologies, Rutishauser (2016) illustrated and discussed various topics of plant evo-devo such as the fuzziness (continuity) of morphological concepts, the lack of a one-to-one correspondence between structural categories and gene expression, the notion of morphospace, the adaptive value of bauplan features versus patio ludens, physiological adaptations, hopeful monsters and saltational evolution, the significance and limits of developmental robustness, etc. Rutishauser (2020) discussed the past and future of plant evo-devo. Our conception of the gynoecium and the search for a fossil ancestor of Angiosperms changes fundamentally from the perspective of evo-devo. Morphological research is influenced by philosophical assumptions such as either/or logic, fuzzy logic, structure/process dualism or its transcendence. Empirical findings may influence the philosophical assumptions, while philosophical assumptions orient the direction of research. These interactions between philosophy and empirical findings are referred to as the philosophy of plant morphology. In 2022, Donal R. Kaplan published Principles of Plant Morphology. It is a major, illustrated collection of morphological data, interpreted in terms of classical morphology and the qualitative homology concept, disregarding modern conceptional innovations. Including continuum and process morphology as well as molecular genetics would provide an enlarged scope.
==== Germany ==== 4-HO-MET is ruled under the Neue-psychoaktive-Stoffe-Gesetz (NpSG) since July 18, 2019. Production and Import with intent to distribute is punishable. Possession is forbidden but not punishable, although ordering it in small quantities can still be seen as an intent to distribute it and be punished. 4-Propionoxy-N-methyl-N-ethyltryptamine (also referred to as 4-PrO-MET) is the ester prodrug of 4-HO-MET. Unlike many other tryptamine derivatives, it is currently not explicitly listed under the German Neue-psychoaktive-Stoffe-Gesetz (NpSG). This means that, while its use as a recreational substance is not legally permitted, the compound may be obtained and handled for legitimate research purposes, provided all other relevant legal requirements and safety regulations are observed.
Labour MP Tam Dalyell commented in Galloway's defence: "I think he is a deeply serious, committed politician and a man of great sincerity about the causes he takes up." On 6 May 2003, David Triesman, then general secretary of the Labour Party, suspended Galloway from holding office in the party pending a hearing on charges that he had violated the party's constitution by "bringing the Labour Party into disrepute through behaviour that is prejudicial or grossly detrimental to the Party." Galloway said he stood by every word of the Abu Dhabi interview. The National Constitutional Committee, responsible for disciplinary matters in the Labour Party, held a hearing on 22 October 2003 to consider the charges, taking evidence from Galloway himself, from other party witnesses, viewing media interviews, and hearing character testimony from former cabinet minister Tony Benn, among others. The following day, the committee unanimously found Galloway guilty of four of the five charges: inciting Arabs to fight British troops, inciting British troops to defy orders, inciting voters to reject Labour MPs, and threatening to stand against Labour. Galloway was expelled from the Labour Party. Galloway said after his expulsion: "This was a politically motivated kangaroo court whose verdict had been written in advance in the best tradition of political show trials". He claimed that other MPs who opposed the war, such as Bob Marshall Andrews and Glenda Jackson, would soon be expelled, but no other MP was expelled from the Labour Party for opposing the Iraq War.
Gutter oil, trench oil, sewer oil, hogwash oil and tainted oil (Chinese: 地沟油 / 地溝油; pinyin: dìgōu yóu, or 餿水油; sōushuǐ yóu) are Chinese slang terms primarily used in China and Taiwan to refer to recycled oil. It can be used to describe the illicit practice of restaurants reusing cooking oil that has already been cooked for longer than safety codes permit. It can also be used to describe the reprocessing of yellow grease collected from sources such as restaurant fryers, kitchen waste, slaughterhouse waste and sewer drains. Since 2011, the Chinese government has significantly cracked down on the reuse of gutter oil for human consumption, with the Chinese government also implementing clearer regulations for dealing with waste oil. Selling gutter oil in China can result in lengthy prison sentences or the death sentence with reprieve. For example, in 2014, businessman Zhu Chuanfeng was sentenced to the latter for selling gutter oil. That same year, a major gutter oil scandal was uncovered in Taiwan. In 2015, Yeh Wen-hsiang, who was the chairman of a Taiwanese food company, was sentenced to 22 years imprisonment and fined NT$50 million (US$1.6 million) for selling 243 tonnes of gutter oil.
Sources: en.wikipedia.org
Dihexa has been proposed to act through HGF and c-Met signaling. This pathway is linked to synapse formation and cellular growth. Direct binding and the precise molecular step remain uncertain.
No published human clinical trials are available for dihexa. Its safety and effectiveness in people are therefore unknown. Most available evidence comes from animal and cell studies.
Preclinical studies often measure dendritic spine density and synaptic protein levels. Behavioral tests include maze learning and avoidance tasks. These endpoints are indirect and do not establish clinical benefit.
It is a synthetic peptide analog of angiotensin IV studied mainly in laboratory and animal research. It is not an approved medicine. Human clinical data are limited.